Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Veeva (VEEV) to $201 from $195 and keeps an Underweight rating on the shares. Veeva beat in Q4 and provided “mixed” guidance for FY26, says the analyst, who adds that operating margin was “a clear bright spot” despite lingering crosscurrents across the Life Sciences vertical. However, there is still a major platform migration to manage through and “work to be done to drive an acceleration in growth implied” by 2030 targets, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems: Strong Performance and Promising Outlook Justify Buy Rating
- Veeva Systems Faces Sell Rating Amid Mixed Outlook and Competitive Pressures
- Balanced Outlook for Veeva Systems: Hold Rating Amidst Mixed Growth Signals
- Veeva Systems Reports Strong Fiscal Year 2025 Growth
- Closing Bell Movers: MongoDB, Marvell Technology down double digits